Marksans Pharma Intrinsic Value
Marksans Pharma (MARKSANS) median intrinsic value is ₹640.30 from 10 valuation models (range ₹96–₹800), vs current price ₹320.15 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Check MARKSANS company valuation to track the company's total market size over time.
MARKSANS Valuation Methods Summary — DCF, Graham Number & P/E
Marksans Pharma intrinsic value across 10 models vs current price ₹320.15 — upside/downside and value range per method. For current market price and key ratios, visit Marksans Pharma stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹287.76 | ₹230.21 - ₹345.31 | -10.1% | EPS: ₹13.08, Sector P/E: 22x |
| Book Value Method | asset | ₹800.38 | ₹720.34 - ₹880.42 | +150.0% | Book Value/Share: ₹678.44, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹640.30 | ₹576.27 - ₹704.33 | +100.0% | Revenue/Share: ₹792.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹640.30 | ₹576.27 - ₹704.33 | +100.0% | EBITDA: ₹924.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹800.38 | ₹640.30 - ₹960.46 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹96.04 | ₹86.44 - ₹105.64 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹202.09 | ₹181.88 - ₹222.30 | -36.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹640.30 | ₹576.27 - ₹704.33 | +100.0% | ROE: 19.5%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹446.84 | ₹402.16 - ₹491.52 | +39.6% | EPS: ₹13.08, BVPS: ₹678.44 |
| Dividend Yield Method | dividend | ₹96.04 | ₹86.44 - ₹105.64 | -70.0% | DPS: ₹0.90, Target Yield: 2.5% |
MARKSANS Intrinsic Value vs Market Price — All Valuation Models
Marksans Pharma fair value range ₹96–₹800 vs current market price ₹320.15 across 10 valuation models. See Marksans Pharma P/B valuation to compare market price against book value per share.
MARKSANS Intrinsic Value Analysis — Undervalued or Overvalued?
Marksans Pharma median intrinsic value ₹640.30, current price ₹320.15 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of MARKSANS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Marksans Pharma (MARKSANS) is ₹640.30 (median value). With the current market price of ₹320.15, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹96.04 to ₹800.38, indicating ₹96.04 - ₹800.38.
Is MARKSANS undervalued or overvalued?
Based on our multi-method analysis, Marksans Pharma (MARKSANS) appears to be trading below calculated value by approximately 100.0%.
MARKSANS Financial Health — Key Ratios vs Industry Benchmarks
Marksans Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.5% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MARKSANS Cash Flow Quality — Operating & Free Cash Flow
Marksans Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹458 Cr | ₹334 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹207 Cr | ₹183 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹230 Cr | ₹160 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹108 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹99 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |